Sugarshaker,
I totally get it. The stock is going through a lull and although you're long, very long, you have no idea how long the lull will last before we hear a clinical update. Maybe the price will get better and maybe it will get worse. The market is so finicky at times. A stock is hot or it's not. And for shareholders to hold while the market isn't paying attention sometimes can be tough. I honestly try not to look during the times any one of my holdings fall below my entry price. I have to say that on this one, I just don't worry. First, TPIV has so many clinical programs going on to bring value, past and present. They also have results that can come out at any time (completed Phase I; updates on trials; conferences and abstracts). My research tells me that combining with a PD1 will prove to be effective. That's always a possible unexpected early surprise. And second, this company is attempting to go after a niche that is actually relatively new to market, vaccinating for a cancer that one hasn't actually been diagnosed with. And while I truly believe that the vaccine can help eliminate (pd1 combo) and keep the deadly disease from returning (solo); my personal view is that the Company's real competitive advantage is that it will end up filling a void that no drug can fill; and that is to treat hereditary at-risk patients, year in and out; sort of like a FRa shot to give woman so they don't get Triple Negative Breast or Ovarian or Colon Cancer. The immune system routinely recognizes and destroys abnormal cells, but cancer cells manage to evade detection and attack. Adding a regiment like TPIV product lines will help to build immune memory, antibodies to seek out and find any cancer cells before it escapes and proliferates. It's a value driver.
So hang in there Sugarshaker, this lull too shall pass. It's totally okay not to add more shares, even if the deal got better. You have to do what makes you most comfortable. If you own too many shares, then there is a chance that you begin to get consumed about what the price is trading at and start worrying why it's not moving up or worse yet, over every reason why it is moving down. No one knows for sure what the future will bring. But I truly believe that you bought a company that offers what others can not, the chance to lower the risk of cancer. And as such little TPIV will get off the OTC, institutional investors will buy in, just as big Pharma and the government has; their studies will proceed and in due time the stock will rise because there is a place for their type of technology in the market place.
Best,
RK
